Annual Total Liabilities
$243.10 M
-$3.94 M-1.59%
December 31, 2023
Summary
- As of February 7, 2025, ADAP annual total liabilities is $243.10 million, with the most recent change of -$3.94 million (-1.59%) on December 31, 2023.
- During the last 3 years, ADAP annual total liabilities has risen by +$133.19 million (+121.17%).
- ADAP annual total liabilities is now -7.77% below its all-time high of $263.58 million, reached on December 31, 2021.
Performance
ADAP Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$237.45 M
+$12.02 M+5.33%
September 30, 2024
Summary
- As of February 7, 2025, ADAP quarterly total liabilities is $237.45 million, with the most recent change of +$12.02 million (+5.33%) on September 30, 2024.
- Over the past year, ADAP quarterly total liabilities has increased by +$3.81 million (+1.63%).
- ADAP quarterly total liabilities is now -9.92% below its all-time high of $263.58 million, reached on December 31, 2021.
Performance
ADAP Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
ADAP Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -1.6% | +1.6% |
| 3 y3 years | +121.2% | +111.0% |
| 5 y5 years | +714.4% | +292.0% |
ADAP Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -7.8% | at low | -9.9% | +16.3% |
| 5 y | 5-year | -7.8% | +319.8% | -9.9% | +310.1% |
| alltime | all time | -7.8% | +6029.4% | -9.9% | +695.4% |
Adaptimmune Therapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $237.45 M(+5.3%) |
| Jun 2024 | - | $225.43 M(-3.5%) |
| Mar 2024 | - | $233.63 M(-3.9%) |
| Dec 2023 | $243.10 M(-1.6%) | $243.10 M(+16.6%) |
| Sep 2023 | - | $208.51 M(-3.6%) |
| Jun 2023 | - | $216.33 M(+5.9%) |
| Mar 2023 | - | $204.21 M(-17.3%) |
| Dec 2022 | $247.04 M(-6.3%) | $247.04 M(+12.9%) |
| Sep 2022 | - | $218.87 M(-11.2%) |
| Jun 2022 | - | $246.35 M(-4.0%) |
| Mar 2022 | - | $256.65 M(-2.6%) |
| Dec 2021 | $263.58 M(+139.8%) | $263.58 M(+134.2%) |
| Sep 2021 | - | $112.55 M(+0.6%) |
| Jun 2021 | - | $111.85 M(+9.2%) |
| Mar 2021 | - | $102.42 M(-6.8%) |
| Dec 2020 | $109.92 M(+89.8%) | $109.92 M(+6.9%) |
| Sep 2020 | - | $102.82 M(-1.7%) |
| Jun 2020 | - | $104.62 M(+5.5%) |
| Mar 2020 | - | $99.20 M(+71.3%) |
| Dec 2019 | $57.91 M | $57.91 M(-4.4%) |
| Sep 2019 | - | $60.57 M(+15.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2019 | - | $52.53 M(+3.4%) |
| Mar 2019 | - | $50.78 M(+70.1%) |
| Dec 2018 | $29.85 M(-61.8%) | $29.85 M(-10.8%) |
| Sep 2018 | - | $33.47 M(-27.5%) |
| Jun 2018 | - | $46.20 M(-17.2%) |
| Mar 2018 | - | $55.81 M(-28.6%) |
| Dec 2017 | $78.16 M(+14.3%) | $78.16 M(+8.0%) |
| Sep 2017 | - | $72.39 M(+32.1%) |
| Jun 2017 | - | $54.78 M(-5.0%) |
| Mar 2017 | - | $57.65 M(-15.7%) |
| Dec 2016 | $68.37 M(+34.5%) | $68.37 M(+60.3%) |
| Sep 2016 | - | $42.64 M(+0.2%) |
| Jun 2016 | - | $42.57 M(-0.1%) |
| Mar 2016 | - | $42.61 M(-8.6%) |
| Dec 2015 | $50.83 M(+22.0%) | - |
| Sep 2015 | - | $46.63 M(+1.7%) |
| Jun 2015 | $41.65 M(-21.6%) | - |
| Dec 2014 | - | $45.85 M(-13.7%) |
| Jun 2014 | $53.11 M(+1239.0%) | $53.11 M |
| Jun 2013 | $3.97 M(-3.0%) | - |
| Jun 2012 | $4.09 M | - |
FAQ
- What is Adaptimmune Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics annual total liabilities year-on-year change?
- What is Adaptimmune Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Adaptimmune Therapeutics?
- What is Adaptimmune Therapeutics quarterly total liabilities year-on-year change?
What is Adaptimmune Therapeutics annual total liabilities?
The current annual total liabilities of ADAP is $243.10 M
What is the all time high annual total liabilities for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high annual total liabilities is $263.58 M
What is Adaptimmune Therapeutics annual total liabilities year-on-year change?
Over the past year, ADAP annual total liabilities has changed by -$3.94 M (-1.59%)
What is Adaptimmune Therapeutics quarterly total liabilities?
The current quarterly total liabilities of ADAP is $237.45 M
What is the all time high quarterly total liabilities for Adaptimmune Therapeutics?
Adaptimmune Therapeutics all-time high quarterly total liabilities is $263.58 M
What is Adaptimmune Therapeutics quarterly total liabilities year-on-year change?
Over the past year, ADAP quarterly total liabilities has changed by +$3.81 M (+1.63%)